Gilead Sciences (GILD) unveiled the results of an interim analysis from a second Phase 3 clinical trial evaluating its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. The study revealed that lenacapavir decreased HIV infections by 96% when compared to the baseline HIV incidence. The independent Data Monitoring Committee (DMC) overseeing the interim analysis confirmed that the PURPOSE 2 trial achieved its primary efficacy endpoints, demonstrating the superiority of biannual lenacapavir over both bHIV and the once-daily oral medication Truvada for pre-exposure prophylaxis. Consequently, the DMC has recommended Gilead terminate the blinded phase of the trial and transition all participants to open-label lenacapavir.Gilead announced that the findings from the PURPOSE 1 and PURPOSE 2 trials will underpin forthcoming regulatory submissions.The material has been provided by InstaForex Company – www.instaforex.com
- Czech Retail Sales Growth Accelerates in August, Reaching 5.30% - October 8, 2024
- Czech Unemployment Rate Sees Slight Uptick in September - October 8, 2024
- France Sees Rise in Imports: August Figures Show a Notable Increase - October 8, 2024
